DA32 Life Science Tech Acquisition Corp.: insider trades · United States · SEC (Form 4)

About DA32 Life Science Tech Acquisition Corp.

DA32 Life Science Tech Acquisition Corp. (ticker: DALS) is a U.S.-listed company trading on the NASDAQ in the United States. It is a special purpose acquisition company, or SPAC, meaning a publicly listed shell vehicle created to complete a merger, stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with a private operating company. According to its SEC filings, DA32 Life Science Tech Acquisition Corp. was incorporated in Delaware on April 16, 2021 and was formed specifically to pursue opportunities in the life sciences technology ecosystem. Its filing history indicates a New York business address at 345 Park Avenue South, 12th Floor, New York, NY 10010, underscoring its U.S.-based financial and transaction-oriented profile. The company’s core strategy is to identify and combine with a target active in life sciences technology, a broad theme that typically includes research tools, laboratory technologies, diagnostics, digital health, and data-enabled biological platforms. Importantly, DA32 is not an operating company with its own commercial product portfolio. Instead, its value proposition lies in sponsor quality, sector expertise, and the ability to source and complete an attractive business combination. In its original IPO materials, the company highlighted a targeted focus on four major life sciences verticals: life science tools, diagnostics, digital health, and data-driven platforms serving biology and healthcare research. From a competitive standpoint, DALS should be viewed within the crowded SPAC universe, where differentiation comes from the reputation of the sponsors, access to proprietary deal flow, and execution capability. The company was launched by a life sciences-focused collaboration involving Deerfield, ARCH, and Section 32, all of which brought investment and operating experience in healthcare and innovation-driven businesses. That sponsor background was designed to give DALS credibility in evaluating science-heavy companies that may require sophisticated structuring and domain-specific diligence. Geographically, DALS is a United States entity with a Delaware incorporation and a New York address, and its listing venue is the NASDAQ. For investors in France, Belgium, and Switzerland, the key point is that this is not a traditional commercial healthcare business but a merger vehicle whose risk/reward profile depends on capital deployment, transaction timing, and the quality of the eventual target. As with many healthcare SPACs, the investment case is highly event-driven: if a deal is announced, the market may re-rate the shares based on the implied valuation, target fundamentals, and redemption dynamics; absent a transaction, the company remains primarily a cash-rich acquisition platform rather than an operating issuer. Recent SEC filings and insider transaction disclosures appear to be the most relevant near-term news flow available for DALS, rather than product launches or operating milestones. That pattern is consistent with a SPAC still focused on capital structure, governance, and business combination activity rather than revenue generation. In short, DALS is best understood as a U.S. NASDAQ-listed life sciences acquisition vehicle with a Delaware legal base, New York presence, and a mandate to create value through a strategic combination in the healthcare innovation landscape.